AU2015340215B2 - Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) - Google Patents

Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) Download PDF

Info

Publication number
AU2015340215B2
AU2015340215B2 AU2015340215A AU2015340215A AU2015340215B2 AU 2015340215 B2 AU2015340215 B2 AU 2015340215B2 AU 2015340215 A AU2015340215 A AU 2015340215A AU 2015340215 A AU2015340215 A AU 2015340215A AU 2015340215 B2 AU2015340215 B2 AU 2015340215B2
Authority
AU
Australia
Prior art keywords
methyl
pyrimidin
pyrido
amino
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015340215A
Other languages
English (en)
Other versions
AU2015340215A1 (en
Inventor
Hae-Sun Kim
Jun Gyu Kim
Myeong-Seop Kim
Taesun Park
Seung Min Yang
Taeyoung Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong-A ST Co Ltd
Original Assignee
Dong-A ST Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong-A ST Co Ltd filed Critical Dong-A ST Co Ltd
Publication of AU2015340215A1 publication Critical patent/AU2015340215A1/en
Application granted granted Critical
Publication of AU2015340215B2 publication Critical patent/AU2015340215B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
AU2015340215A 2014-10-29 2015-10-27 Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) Active AU2015340215B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462069915P 2014-10-29 2014-10-29
US62/069,915 2014-10-29
PCT/KR2015/011386 WO2016068580A2 (en) 2014-10-29 2015-10-27 Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)

Publications (2)

Publication Number Publication Date
AU2015340215A1 AU2015340215A1 (en) 2017-04-13
AU2015340215B2 true AU2015340215B2 (en) 2018-11-15

Family

ID=55851908

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015340215A Active AU2015340215B2 (en) 2014-10-29 2015-10-27 Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs)

Country Status (13)

Country Link
US (1) US9834550B2 (enExample)
EP (1) EP3212647B1 (enExample)
JP (1) JP6505222B2 (enExample)
KR (1) KR101978899B1 (enExample)
CN (1) CN107001358A (enExample)
AU (1) AU2015340215B2 (enExample)
BR (1) BR112017008312A2 (enExample)
CA (1) CA2962917C (enExample)
MX (1) MX2017005346A (enExample)
NZ (1) NZ730475A (enExample)
RU (1) RU2684396C2 (enExample)
SG (1) SG11201702075QA (enExample)
WO (1) WO2016068580A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6853819B2 (ja) * 2015-10-08 2021-03-31 スーチョウ ユンシュアン イーヤオ カジ ヨウシェン ゴンス Ｗｎｔシグナル伝達経路阻害剤およびその治療用途
US10221191B2 (en) 2015-12-22 2019-03-05 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
SG11201911929XA (en) 2017-06-21 2020-01-30 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020011086A1 (zh) * 2018-07-13 2020-01-16 四川科伦博泰生物医药股份有限公司 苯并二氮杂环类化合物、其制备方法及用途
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
EP4098650B1 (en) 2020-01-31 2025-12-10 Kumiai Chemical Industry Co., Ltd. 3-alkoxy benzoic acid amide derivative, and pest control agent
EP4126847A1 (en) 2020-03-30 2023-02-08 ENYO Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
JP7768592B2 (ja) * 2021-03-31 2025-11-12 デューク ストリート バイオ リミテッド 医薬化合物
GB202114315D0 (en) * 2021-10-06 2021-11-17 Duke Street Bio Ltd Pharmaceutical compound

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001441A1 (en) * 1997-07-01 1999-01-14 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
WO2000064424A2 (en) * 1999-04-22 2000-11-02 University Of Wales College Of Medicine Cystic fibrosis medicaments
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
WO2007117161A1 (en) * 2006-04-07 2007-10-18 Auckland Uniservices Limited Substituted ring fused azines and their use in cancer therapy
WO2013012915A1 (en) * 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103694255A (zh) * 2014-01-09 2014-04-02 华中师范大学 吡啶并噁嗪酮和吡啶并嘧啶酮类化合物及其制备方法与应用
WO2014052699A1 (en) * 2012-09-28 2014-04-03 Cephalon, Inc. Azaquinazoline inhibitors of atypical protein kinase c
WO2014087165A1 (en) * 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
WO2015148597A1 (en) * 2014-03-25 2015-10-01 Ignyta, Inc. Azaquinazoline inhibitors of atypical protein kinase c

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045911A1 (en) * 2001-11-26 2003-06-05 Dsm Ip Assets B.V. Process for recovering caprolactam
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20150272939A1 (en) 2012-10-02 2015-10-01 Yale University Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase
HRP20170358T1 (hr) 2012-10-02 2017-04-21 Gilead Sciences, Inc. Inhibitori histonskih demetilaza
ES2670864T3 (es) 2013-02-27 2018-06-01 Gilead Sciences, Inc. Inhibidores de histonas desmetilasas
WO2014164708A1 (en) 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone dementhylase inhibitors
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
PL2970211T3 (pl) 2013-03-15 2018-01-31 Quanticel Pharmaceuticals Inc Inhibitory demetylazy histonowej
EP3041474B1 (en) 2013-09-05 2020-03-18 Genentech, Inc. Antiproliferative compounds

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001441A1 (en) * 1997-07-01 1999-01-14 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
WO2000064424A2 (en) * 1999-04-22 2000-11-02 University Of Wales College Of Medicine Cystic fibrosis medicaments
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
WO2007117161A1 (en) * 2006-04-07 2007-10-18 Auckland Uniservices Limited Substituted ring fused azines and their use in cancer therapy
WO2013012915A1 (en) * 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2014052699A1 (en) * 2012-09-28 2014-04-03 Cephalon, Inc. Azaquinazoline inhibitors of atypical protein kinase c
WO2014087165A1 (en) * 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
CN103694255A (zh) * 2014-01-09 2014-04-02 华中师范大学 吡啶并噁嗪酮和吡啶并嘧啶酮类化合物及其制备方法与应用
WO2015148597A1 (en) * 2014-03-25 2015-10-01 Ignyta, Inc. Azaquinazoline inhibitors of atypical protein kinase c

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAS RN 1437433-79-8, STN Entry Date 13 June 2013 *
CAS RN 1437434-95-1, STN Entry Date 13 June 2013 *
CAS RN 1437481-06-5, STN Entry Date 13 June 2013 *
CAS RN 1437483-85-6, STN Entry Date 13 June 2013 *
HAYAKAWA, M. et al., "Synthesis and biological evaluation of 4-morpholino-2 -phenylquinazolines and related derivatives as novel PI3 kinase p11alpha inhib itors", Bioorganic & Medicinal Chemistry, (2006-07-11), vol. 14, pages 6847 - 6858 *

Also Published As

Publication number Publication date
SG11201702075QA (en) 2017-04-27
CA2962917C (en) 2019-04-30
KR20170072943A (ko) 2017-06-27
RU2684396C2 (ru) 2019-04-09
CN107001358A (zh) 2017-08-01
US20160122343A1 (en) 2016-05-05
WO2016068580A3 (en) 2016-08-18
EP3212647A4 (en) 2018-04-18
EP3212647A2 (en) 2017-09-06
AU2015340215A1 (en) 2017-04-13
US9834550B2 (en) 2017-12-05
NZ730475A (en) 2018-09-28
RU2017113007A3 (enExample) 2018-11-29
MX2017005346A (es) 2017-08-02
RU2017113007A (ru) 2018-11-29
KR101978899B1 (ko) 2019-05-15
CA2962917A1 (en) 2016-05-06
JP2017533215A (ja) 2017-11-09
WO2016068580A2 (en) 2016-05-06
JP6505222B2 (ja) 2019-04-24
EP3212647B1 (en) 2019-04-03
BR112017008312A2 (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
AU2015340215B2 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs)
EP3137169B1 (en) Inhibitors of lysine specific demethylase-1
EP3160956B1 (en) Inhibitors of lysine specific demethylase-1
EP2970211B1 (en) Histone demethylase inhibitors
EP3164380B1 (en) Inhibitors of lysine specific demethylase-1
EP3405192B1 (en) Bruton's tyrosine kinase inhibitors
CA2697081A1 (en) 5-(4-(haloalkoxy)phenyl)pyrimidine-2-amine compounds and compositions as kinase inhibitors
KR20190133199A (ko) 브루톤 타이로신 키나제 억제제
WO2017034377A1 (en) Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
HK1235787A1 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
HK1235332B (en) Inhibitors of lysine specific demethylase-1
HK1235332A1 (en) Inhibitors of lysine specific demethylase-1
HK1231860A1 (en) Inhibitors of lysine specific demethylase-1
HK1231860B (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)